by The global gastroparesis treatment market, valued at $6.94 billion in 2025, is projected to reach nearly $10.45 billion by 2034, growing at a compound annual growth rate (CAGR) of 4.65% over the forecast period. The steady upward trend is powered by the rising prevalence of diabetes-induced gastric dysfunction, increased demand for minimally invasive devices, advances in prokinetic medications, and global awareness efforts. Medical professionals are focusing on early diagnosis, and the market’s innovation pipeline is expanding to meet these urgent needs.
Gastroparesis Treatment Market Quick Insights
-
The worldwide gastroparesis treatment market will hit $10.45 billion by 2034.
-
North America dominates due to advanced diagnostics and high awareness among gastroenterologists.
-
Asia Pacific is the fastest-growing market, spurred by healthcare modernization and diabetes rates.
-
Pharmacological therapies hold the largest market share, with prokinetic agents accounting for 40% of treatment revenues in 2024.
-
Diabetic gastroparesis remains the leading disease segment, driven by diabetes prevalence.
-
Hospitals are the primary end users, supporting complex case management with advanced diagnostics.
-
Hospital pharmacies are the top distribution channel; online pharmacies will see the fastest growth due to digital adoption.
-
U.S. market alone will reach $3.13 billion by 2034, with a higher growth rate of 4.85% CAGR.
Revenue Breakdown Table
| Year | Global Market Value (USD) | U.S. Market Value (USD) | CAGR (Global) | Dominant Region |
|---|---|---|---|---|
| 2024 | $6.63 Billion | $1.95 Billion | – | North America |
| 2025 | $6.94 Billion | $2.14 Billion | 4.65% (2025-34) | North America |
| 2034 | $10.45 Billion | $3.13 Billion | 4.65% (Global) | North America |
Artificial intelligence is beginning to reshape the gastroparesis treatment landscape in two vital areas:
-
Diagnostics: AI-driven machine learning models now anticipate post-operative risks, allowing clinicians to tailor surgical plans and proactively minimize complications. AI also powers advanced diagnostic imaging—such as endoscopic visual analysis—enabling quicker and more accurate differentiation between similar disorders like functional dyspepsia and gastroparesis, though real-world clinical validation continues to evolve.
-
Personalized Care: Emerging innovations in AI hold promise for identifying new biomarkers and creating individualized treatment plans based on patient data, potentially unlocking dramatically improved diagnostic accuracy and outcomes for gastroparesis sufferers.
What’s Fueling Market Growth?
Diabetes Epidemic: The Stealth Driver
Rising global diabetes rates are the leading force behind increased gastroparesis prevalence. Clinical studies highlight how poor glycemic control leads to delayed gastric emptying, mandating proactive screening and improving early disease detection.
Technological Advancements
Greater accessibility to diagnostic imaging—such as gastric emptying scintigraphy and motility capsules—plus the development of new prokinetic drugs and minimally invasive procedures, are helping broaden patient reach and treatment effectiveness.
Expanding Healthcare Infrastructure
Especially pronounced in Asia Pacific, modernization and growing access to tertiary care are increasing diagnostic and therapeutic uptake, reducing timelines from diagnosis to treatment.
What Opportunities and Trends Are Shaping the Market?
Is AI the Breakthrough Gastroparesis Diagnosis Has Been Waiting For?
Early results suggest AI may soon deliver game-changing precision in identifying gastroparesis and related disorders. From visual diagnostics to individualized care plans, digital approaches continue to accelerate research, regulatory approvals, and adoption of innovative therapies.
Can Shortages Spark Innovation?
Recent domperidone shortages in the U.S. have created demand for alternatives like GIMOTI® nasal spray (metoclopramide), which has cut ER visits by 60% and hospitalizations by 68%. This dynamic is opening the door for smart capsules and neuromodulatory devices under development, including MIT’s swallowable capsule for targeted electrical stimulation of the gut.
Will Non-Invasive Therapies Overtake Traditional Approaches?
As clinicians and patients increasingly prefer less-invasive therapies, device-based treatments—like gastric electrical stimulation—are gaining momentum in severe cases. Improvements in device technology and favorable reimbursement climates could accelerate adoption.
Gastroparesis Treatment Market Regional & Segmentation Analysis: Where Does Momentum Lie?
North America
Home to cutting-edge diagnostics, rapid treatment pipelines, and multi-disciplinary teams, the region leads the market in both value and innovation. U.S. hospitals feature advanced motility testing and are expanding access to minimally invasive procedures like G-POEM, with high clinical trial density streamlining regulatory approvals.
Asia Pacific
While North America dominates, Asia Pacific is growing fastest—thanks to lifestyle changes, urbanization, and healthcare infrastructure upgrades, especially in China. Academic-blackened clinical guidelines and government-funded modernization see rates of diagnosis and treatment rising sharply.
Segmentation Breakdown
-
By Treatment Type: Pharmacological therapies dominate (40% revenue share in 2024); device-based therapies rapidly advancing.
-
By Disease Type: Diabetic gastroparesis leads; idiopathic cases (unknown cause) expected to grow fastest.
-
By End User: Hospitals stand as primary care centers; specialty clinics are growing in prominence.
-
By Distribution Channel: Hospital pharmacies most dominant, while online sales gain rapid traction.
Latest Breakthroughs and Company Highlights
-
GIMOTI® (Evoke Pharma): FDA-approved nasal spray for diabetic gastroparesis, showing significant ER and hospitalization reduction.
-
MIT’s Swallowable Smart Capsule: Experimental device delivers electrical pulses to stimulate gastric motility, with promising animal trial results.
Gastroparesis Treatment Market Top Companies
-
Evoke Pharma (GIMOTI®)
-
MIT (Research Capsule Developments)
What Are the Market’s Pain Points?
Challenge: Existing therapies have limited efficacy, notable side effects, and no curative options, often leading to patient dissatisfaction and medication discontinuation. Restricted treatment choices and incomplete engagement continue to hold back market potential, even as prevalence rises.
Cost Pressures: Device costs and pharmaceuticals pricing—especially with supply shortages—impact both hospital budgets and patient access. Reimbursement and insurance coverage remain critical in shaping future market landscapes.
Case Study: GIMOTI® Optimizes Patient Outcomes
A recent real-world study on GIMOTI® (metoclopramide nasal spray) revealed a 60% reduction in emergency room visits and a 68% decrease in hospitalizations post-treatment—underscoring its value in managing diabetic gastroparesis and responding rapidly to medication shortages.
Read Also: Glass Interposers Market
You can place an order or ask any questions, please feel free to contact us at sales@precedenceresearch.com |+1 804 441 9344
- Gastroparesis Treatment Market Poised for Transformative Growth: Reaches $10.45 Billion by 2034 - August 20, 2025
- Glass Interposers Market Empower semiconductor packaging with high-performance 2.5D/3D integration and APAC-led scale - August 20, 2025
- Diabetes Nutrition Market Empower patient management with personalized dietary solutions and functional innovations - August 19, 2025
